Skip to main content
HCPCS J9278 · Level II · Part B drug

HCPCS J9278: Injection, carboplatin (avyxa), 1 mg

Reviewed by QuickIntell RCM Editorial Team · Last reviewed

Data effective
Data currency: ASP payment limits October 2026 (effective October 1, 2026); MUE and NCCI edits 2026 Q4 (effective October 1, 2026); OPPS Addendum B July 2026 (effective July 1, 2026). Next CMS release: January 1, 2027 (ASP, MUE, NCCI and OPPS quarterly updates).

Key facts for J9278

Billing unit
1 MG
Inj, carboplatin (avyxa)
ASP payment limit
$5.226
October 2026; +0.4% vs July 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI G
APC 0917
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J9278 is the Level II code for Injection, carboplatin (avyxa), 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $5.226 per billing unit, up 0.4% from July 2026. Under OPPS it carries status indicator G in APC 0917. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 3 NDCs to it, sold as Kyxata by Avyxa Pharma, LLC. No current Billing and Coding Article lists J9278, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J9278 at $5.226 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%, compared with $5.203 in July 2026. Beneficiary coinsurance is 20%.

ASP payment limits for J9278
QuarterPayment limitPerCoinsurance
October 2026$5.2261 MG20%
July 2026$5.2031 MG—
Source: CMS Medicare Part B Drug Payment Limit File. Commercial and Medicaid payers set their own rates.

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 3 NDCs from 1 labeler to J9278. Report the NDC in the claim's drug segment and bill the number of J9278 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J9278
NDCDrug nameLabelerPackage sizeBilling units / package
83831-0140-02KyxataAvyxa Pharma, LLC2 × 120
83831-0141-08KyxataAvyxa Pharma, LLC8 × 180
83831-0142-50KyxataAvyxa Pharma, LLC50 × 1500

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for J9278 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J9278 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

J9278 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J9278 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the July 2026 OPPS Addendum B, J9278 carries status indicator G and is assigned to APC 0917, with a published national unadjusted payment of $5.20. Status G marks pass-through drug payment, which is time-limited.

Common denials for J9278 and how to prevent them

CARC 16 · M119

NDC missing, invalid or not matched to the HCPCS code

CARC 151 · N362

units billed exceed the MUE for the date of service

CARC 50 · N115

diagnosis not covered by the applicable coverage article or LCD

How QuickIntell checks J9278 before the claim leaves

QuickCode validates the NDC-to-unit conversion against the current ASP crosswalk, checks units against every published MUE setting and flags PTP and add-on conflicts on the same claim. QuickRCM routes CARC 16, 151 and 50 denials on drug lines with the matching coverage article attached so the appeal starts with evidence.

Explore QuickCodeExplore QuickRCMBook a meeting

Frequently asked questions — HCPCS J9278

What does HCPCS code J9278 describe?

J9278 is defined by CMS as "Injection, carboplatin (avyxa), 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

What is the Medicare reimbursement for J9278 in October 2026?

The ASP-based payment limit is $5.226 per 1 MG, with 20% beneficiary coinsurance. Medicare Administrative Contractors apply this limit; commercial payers use their own fee schedules. The July 2026 limit was $5.203.

Which NDCs map to J9278?

The October 2026 ASP crosswalk lists 3 NDCs from 1 labeler: Kyxata (Avyxa Pharma, LLC). For example NDC 83831-0140-02 is a 2 package equal to 20 billing units. The crosswalk's billing-units-per-package figure converts each package into J9278 units.

Does J9278 have NCCI bundling edits?

No active practitioner PTP pairs list J9278 as a column-1 or column-2 code in the v323r0 release. Unit limits (MUE) and medical-necessity coverage rules still apply.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-10-02. Verify against the primary file before billing or contracting decisions.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B and the Medicare Coverage Database. Payment limits are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.